TruSight Hereditary Cancer Panel by Illumina: Unraveling Genetic Insights for Informed Cancer Management
In the realm of precision oncology, the TruSight Hereditary Cancer Panel from Illumina stands at the forefront, offering a powerful genomic solution to empower individuals and families. AmpliSeq, a cornerstone of this comprehensive panel, delivers an in-depth analysis of BRCA1/2 germline mutations, revolutionizing personalized cancer risk assessment and treatment strategies.
AmpliSeq within the TruSight Hereditary Cancer Panel is not just a test; it’s a transformative tool that tailors oncological treatments and assesses hereditary mutation risks within families. By providing unparalleled genetic insights, it empowers healthcare providers and individuals to make informed decisions, ushering in a new era of personalized healthcare.
Whether seeking diagnostic support for precise treatment or predictive analysis for comprehensive family-wide risk assessments, AmpliSeq is your ally in the journey towards more informed and personalized healthcare decisions. Illuminate the path to a healthier future with TruSight Hereditary Cancer Panel by Illumina.
Comprehensive BRCA1/2 Analysis:
AmpliSeq harnesses the precision of Next-Generation Sequencing (NGS) for comprehensive BRCA1/2 germline mutation analysis. This not only guides the necessity of targeted therapies but also informs decisions on potential surgical interventions, ensuring optimal cancer management.
Diagnostic Support for Patients:
Serving as a beacon of support for patients, AmpliSeq conducts diagnostic analysis, unraveling the genetic intricacies that dictate the most effective precision oncology treatment. It transforms genetic data into actionable insights, paving the way for tailored and effective therapeutic approaches.
Predictive Analysis for Families:
AmpliSeq extends its impact beyond individuals, conducting predictive analysis on family members. This empowers healthcare providers and families to assess the likelihood of inherited mutation risks, fostering proactive healthcare planning and informed decision-making.
- Tissue Samples for Patients
- Blood Samples for Family Members
This versatile range of examination types and sample sources exemplifies the adaptability and inclusivity of AmpliSeq within the TruSight Hereditary Cancer Panel.
Benefits of TruSight Oncology 500 Portfolio
Includes 10,341 probes that target 113 genes related to cancer predisposition research.
TruSight Hereditary Cancer Panel includes 125 SNPs. Of these, 48 are ID SNPs and 77 are used for polygenic risk scoring (PRS) research.
In combination with Illumina DNA Prep with Enrichment, TruSight Hereditary Cancer Panel enables genetic labs to prepare hybrid capture sequencing libraries in 6.5 hours with limited hands on time of ~2 hours.
Accommodates flexible workflows and is compatible with different sources of samples such as genomic DNA, saliva (Oragene tubes) or blood (Flex Lysis Reagent). It is compatible with all Illumina benchtop sequencers, and allows for maximum flexibility for batching from 2 to 256 samples.